SG11202108488SA - Istaroxime-containing intravenous formulation for the treatment of acute heart failure (ahf) - Google Patents
Istaroxime-containing intravenous formulation for the treatment of acute heart failure (ahf)Info
- Publication number
- SG11202108488SA SG11202108488SA SG11202108488SA SG11202108488SA SG11202108488SA SG 11202108488S A SG11202108488S A SG 11202108488SA SG 11202108488S A SG11202108488S A SG 11202108488SA SG 11202108488S A SG11202108488S A SG 11202108488SA SG 11202108488S A SG11202108488S A SG 11202108488SA
- Authority
- SG
- Singapore
- Prior art keywords
- istaroxime
- ahf
- treatment
- heart failure
- acute heart
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/009—Sachets, pouches characterised by the material or function of the envelope
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814149P | 2019-03-05 | 2019-03-05 | |
| PCT/US2019/060961 WO2020180356A1 (en) | 2019-03-05 | 2019-11-12 | Istaroxime-containing intravenous formulation for the treatment of acute heart failure (ahf) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202108488SA true SG11202108488SA (en) | 2021-09-29 |
Family
ID=69160228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202108488SA SG11202108488SA (en) | 2019-03-05 | 2019-11-12 | Istaroxime-containing intravenous formulation for the treatment of acute heart failure (ahf) |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11197869B2 (en) |
| EP (1) | EP3934654A1 (en) |
| JP (1) | JP7560134B2 (en) |
| KR (1) | KR20210136048A (en) |
| CN (1) | CN112118846B (en) |
| AU (1) | AU2019432709A1 (en) |
| BR (1) | BR112021017009A2 (en) |
| CA (1) | CA3130261A1 (en) |
| IL (1) | IL285921A (en) |
| MX (1) | MX2021010483A (en) |
| SG (1) | SG11202108488SA (en) |
| WO (1) | WO2020180356A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3805243B1 (en) * | 2019-10-09 | 2023-11-15 | Windtree Therapeutics, Inc. | Androstane derivatives with activity as pure or predominantly pure stimulators of serca2a for the treatment of heart failure |
| TW202245792A (en) * | 2021-01-22 | 2022-12-01 | 美商風樹療法公司 | Intravenous istaroxime for the treatment of acute heart failure |
| WO2023205183A1 (en) | 2022-04-20 | 2023-10-26 | Windtree Therapeutics, Inc. | Istaroxime-containing intravenous formulation for the treatment of pre-cardiogenic shock and cardiogenic shock |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4534899A (en) | 1981-07-20 | 1985-08-13 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
| US5846743A (en) | 1995-02-22 | 1998-12-08 | Brigham And Women's Hospital, Inc. | Polyphoshoinositide binding peptides for intracellular drug delivery |
| US6007839A (en) | 1996-02-16 | 1999-12-28 | The Liposome Company, Inc. | Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes |
| DE19633349A1 (en) | 1996-08-19 | 1998-02-26 | Sigma Tau Ind Farmaceuti | New 6-hydroxy and 6-oxo-androstane derivatives that act on the cardiovascular system and pharmaceutical compositions containing them |
| US5874268A (en) | 1996-09-23 | 1999-02-23 | Duke University | Method of introducing exogenous compounds into cells by electroporation and apparatus for same |
| US6630137B1 (en) | 1997-04-28 | 2003-10-07 | Eli Lilly And Company | Activated protein C formulations |
| JP2000516641A (en) | 1997-07-02 | 2000-12-12 | エスディージー インコーポレイテッド | Targeted liposome constructs for diagnostic and therapeutic applications |
| SE9704076D0 (en) | 1997-11-06 | 1997-11-06 | Holdingbolaget Vid Goeteborgs | Method for permeabilization of cell structures and use thereof |
| US6589503B1 (en) | 1998-06-20 | 2003-07-08 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
| IT1317031B1 (en) | 2000-05-17 | 2003-05-26 | Sigma Tau Ind Farmaceuti | IMPROVED PROCEDURE FOR THE PREPARATION OF (E, Z) 3- (2-AMINO-ETHOXY) -ANDROSTANE-6, 17-DIONE AND ITS ANALOGUES. |
| US20040151766A1 (en) | 2003-01-30 | 2004-08-05 | Monahan Sean D. | Protein and peptide delivery to mammalian cells in vitro |
| WO2005063156A1 (en) | 2003-12-22 | 2005-07-14 | Shear/Kershman Laboratories, Inc. | Oral peptide delivery system with improved bioavailability |
| EP1698329A4 (en) | 2003-12-24 | 2009-10-28 | Ltt Bio Pharma Co Ltd | Drug-containing nanoparticle, process for producing the same and parenterally administered preparation from the nanoparticle |
| US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
| JP4758915B2 (en) | 2004-08-06 | 2011-08-31 | バイオスペクトラム，インコーポレイテッド | Multilamellar liposome and production method thereof |
| JP4959570B2 (en) | 2004-10-18 | 2012-06-27 | 日東電工株式会社 | Intracellular peptide delivery |
| US9005654B2 (en) | 2005-07-27 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Systems and methods for manufacturing liposomes |
| US20100087374A1 (en) * | 2008-10-03 | 2010-04-08 | Shama Ahmad | Methods for Treatment and Diagnosis of Pulmonary Diseases Based on the Expression of SERCA2 Protein |
| WO2010040110A1 (en) * | 2008-10-03 | 2010-04-08 | Pericor Therapeutics, Inc. | Methods and compositions for treatment of acute heart failure |
| CA2889584C (en) * | 2012-10-26 | 2018-08-14 | The Medicines Company | Methods for controlling blood pressure and reducing dyspnea in heart failure |
| US20160151461A1 (en) * | 2013-03-14 | 2016-06-02 | The Trustees Of The University Of Pennsylvania | Cardio-Metabolic and Vascular Effects of GLP-1 Metabolites |
| CN103315968B (en) * | 2013-06-26 | 2015-04-01 | 中国生命药物治疗有限公司 | Powder injection for injection and preparation method thereof |
| TW202245792A (en) * | 2021-01-22 | 2022-12-01 | 美商風樹療法公司 | Intravenous istaroxime for the treatment of acute heart failure |
-
2019
- 2019-11-12 CN CN201980003356.1A patent/CN112118846B/en active Active
- 2019-11-12 EP EP19836196.6A patent/EP3934654A1/en active Pending
- 2019-11-12 BR BR112021017009A patent/BR112021017009A2/en unknown
- 2019-11-12 KR KR1020217031262A patent/KR20210136048A/en unknown
- 2019-11-12 CA CA3130261A patent/CA3130261A1/en active Pending
- 2019-11-12 MX MX2021010483A patent/MX2021010483A/en unknown
- 2019-11-12 AU AU2019432709A patent/AU2019432709A1/en active Pending
- 2019-11-12 WO PCT/US2019/060961 patent/WO2020180356A1/en active Application Filing
- 2019-11-12 SG SG11202108488SA patent/SG11202108488SA/en unknown
- 2019-11-12 JP JP2021552770A patent/JP7560134B2/en active Active
-
2021
- 2021-04-16 US US17/233,302 patent/US11197869B2/en active Active
- 2021-08-29 IL IL285921A patent/IL285921A/en unknown
- 2021-11-02 US US17/517,530 patent/US11583540B2/en active Active
-
2023
- 2023-01-06 US US18/150,870 patent/US20230293548A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230293548A1 (en) | 2023-09-21 |
| WO2020180356A1 (en) | 2020-09-10 |
| US20210252017A1 (en) | 2021-08-19 |
| US11583540B2 (en) | 2023-02-21 |
| MX2021010483A (en) | 2021-10-01 |
| AU2019432709A1 (en) | 2021-09-02 |
| KR20210136048A (en) | 2021-11-16 |
| US11197869B2 (en) | 2021-12-14 |
| CN112118846A (en) | 2020-12-22 |
| IL285921A (en) | 2021-10-31 |
| JP2022523821A (en) | 2022-04-26 |
| WO2020180356A9 (en) | 2020-11-12 |
| BR112021017009A2 (en) | 2021-11-09 |
| JP7560134B2 (en) | 2024-10-02 |
| CA3130261A1 (en) | 2020-09-10 |
| EP3934654A1 (en) | 2022-01-12 |
| US20220054502A1 (en) | 2022-02-24 |
| CN112118846B (en) | 2024-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285921A (en) | Istaroxime-containing intravenous formulation for the treatment of acute heart failure (ahf) | |
| IL273169A (en) | New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild) | |
| AU2014375637A1 (en) | Formula of neuregulin preparation | |
| IL260955A (en) | Minitablet for oral administration comprising sacubitril and valsartan for the treatment of heart failure | |
| IL282007A (en) | Medicament for the treatment of chronic cough | |
| EP3841086A4 (en) | Pharmaceutical compounds for the treatment of complement factor d medical disorders | |
| IL283931A (en) | Sulcardine administration for treatment of acute atrial fibrillation | |
| MX2017015664A (en) | Intravenous administration of citrulline during surgery. | |
| EP3846843A4 (en) | Compositions and methods for the treatment of heart disease | |
| MX2020003243A (en) | Methods of treating heart failure with preserved ejection fraction. | |
| EP3661502A4 (en) | Compounds for the prevention and treatment of medical disorders and uses thereof | |
| EP3619204A4 (en) | Compounds for the treatment of respiratory diseases | |
| EP3923963A4 (en) | Treating heart failure | |
| EP3259346A4 (en) | P63 inactivation for the treatment of heart failure | |
| IL291412A (en) | Androstane derivatives with activity as pure or predominantly pure stimulators of serca2a for the treatment of heart failure | |
| IL277141A (en) | Compounds for treatment of cardiac arrhythmias and heart failure | |
| IL282930A (en) | Catheter for intravascular blood pump | |
| IL275273A (en) | Improved compound for treatment of heart failure | |
| EP4069251A4 (en) | Salts and polymorphs of cethromycin for the treatment of disease salts and polymorphs of cethromycin | |
| EP3932487A4 (en) | External preparation for vascular abnormality treatment | |
| EP3690054A4 (en) | Pharmaceutical composition for prevention or treatment of heart failure | |
| EP3846803A4 (en) | Macrocyclic compounds for the treatment of medical disorders | |
| EP3514235B8 (en) | Composition for the treatment of a patient suffering from ulcerative colitis and utilisation of said composition as medicament | |
| IL280243A (en) | 17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure | |
| GB202111861D0 (en) | Materials for the treatment of medical conditions |